HCPCS Q2056 is officially defined as "Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose." HCPCS Q2056 is referenced in 2 tracked payer policy changes from CareSource and Humana. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS Q2056 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Related
Get alerts for changes like this
Save a search and receive a daily digest whenever a new policy change matches your filters.